TrialInternational journal of clinical oncology2017

A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.

Tomomi Kamba et al.PubMed ↗Publisher ↗

No numbers read from the abstract.